Skip to main content

Press releases | November 30, 2023

Fried Frank acted as counsel to Goldman Sachs and Lazard as financial advisors to ImmunoGen, Inc. (NASDAQ: IMGN) in its $10.1 billion acquisition by AbbVie Inc. (NYSE: ABBV). AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE® (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC). The acquisition accelerates AbbVie's commercial and clinical presence in the solid tumor space. Additionally, ImmunoGen's follow-on pipeline of promising next-generation ADCs further complements AbbVie's ADC platform and existing programs. 

The Fried Frank team was led by partner Roy Tannenbaum.


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.